Poolbeg Pharma在1 000万英镑现金余额、4 900万英镑资金和FDA主要药物孤儿药物状况上获得了3%的收益,推进了2026年的试验。 Poolbeg Pharma gained 3% on a £10M cash balance, £4.9M funding, and FDA orphan drug status for its lead drug, advancing its 2026 trial.

Poolbeg Pharma PLC股份上升了3%,因为该公司报告有1 000万英镑的现金余额,并获得490万英镑超额注资,将其跑道延长到2027年。 Poolbeg Pharma PLC shares rose 3% as the company reported a £10 million cash balance and secured £4.9 million in oversubscribed funding, extending its runway into 2027. 其主要候选人POLB 001接受了美国FDA孤儿药品指认,以防止癌症免疫疗法中细胞释放综合症,促进临床发展。 Its lead candidate, POLB 001, received U.S. FDA Orphan Drug Designation for preventing cytokine release syndrome in cancer immunotherapy, advancing its clinical development. 该公司正在筹备第2a阶段的试验,预计2026年夏季将提供临时数据。 The company is preparing for a Phase 2a trial, with interim data expected in summer 2026.